Evidence analysisNovember 17, 2026Health & Science

Towards improving the safety of medication use in pregnancy

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

Towards Improving the Safety of Medication Use in Pregnancy: Evidence Dossier

What is established

Pregnant individuals have traditionally been excluded from clinical trials, leaving a significant gap in knowledge regarding the safety and risks of medication use during pregnancy. This exclusion dates back at least to the mid-20th century and was highlighted tragically by the thalidomide tragedy, where a medication prescribed for morning sickness caused severe fetal malformations.

Currently, over half of pregnant people use prescribed medication—for example, antiemetics, antibiotics, and analgesics—with reported prevalence around 56% or higher when over-the-counter drugs and supplements are included. The trend of higher maternal age and increasing chronic conditions is expected to further increase medication exposure during pregnancy.

Most available safety data during pregnancy derive from observational studies rather than controlled trials, due to ethical and practical barriers in enrolling pregnant individuals. Observational evidence includes studies that have not found strong associations between certain medications (like NSAIDs and some antibiotics) and major congenital malformations, but also some inconclusive findings, such as potential links between asthma medications and neurodevelopmental outcomes.

What the source claims

The PLOS Medicine editorial by Jardine and de Bruijn argues that despite some recent regulatory openness to including pregnant individuals in trials, clinical research remains insufficient to fill knowledge gaps. Observational studies thus remain essential but require rigorous design, methodological consistency, and harmonized data collection to be maximally informative.

The authors emphasize several challenges:

  • Confounding by indication: Underlying maternal illness necessitating treatment may itself harm fetal outcomes, complicating assessment of drug risk vs. benefit.
  • Physiological and temporal complexity: Pregnancy involves dynamic biological changes and varied timing of exposure, requiring sophisticated temporal modeling.
  • Long-term outcomes: Some adverse effects, such as neurodevelopmental disorders, manifest years after birth, demanding longitudinal follow-up.
  • Limited trial inclusion: Pregnant people represented only 1.1% of clinical trial applications in the UK (2019–2023), limiting generalizable trial evidence.
  • Data harmonization and accessibility: Calls for comprehensive registries covering all pregnancy-related exposures, better linkage of maternal-child health records, standardized reporting of gestational age and dose, and possibly regulatory mandates for post-marketing registry studies.

The editorial also points to complementary pharmacological methods, such as placental transfer studies and biomarker measurements, which can help prioritize safety questions and clarify biological plausibility of associations observed in epidemiological studies.

What may be missing from the usual framing

The article highlights the complexity of balancing maternal health needs and fetal safety, a nuance sometimes underemphasized in public discourse focused largely on fetal risk. It notes that withholding treatment may itself be harmful, especially for serious maternal conditions, but this aspect can be overshadowed in risk narratives.

Moreover, it stresses the geographic and socioeconomic disparity in data availability and study feasibility. Most advanced pharmacoepidemiological research is concentrated in higher-income settings, which may limit the applicability of findings in low- and middle-income countries with differing healthcare contexts and risk factors.

The editorial implicitly critiques the reliance on slow, fragmented data collection and reactive rather than proactive safety evaluation, proposing systematic, coordinated approaches that challenge current regulatory and research norms.

Competing evidence or uncertainty

Observational studies offer valuable but inherently limited evidence due to confounding factors and challenges in establishing causality. While some studies indicate no major malformation risks with commonly used medications, others report potential associations with neurodevelopmental outcomes, though often with uncertainty about whether these are due to medication effects or the conditions being treated.

The evidence base remains insufficiently large or conclusive for many medications, and no clear-cut safety verdict exists for many drugs. Regulatory agencies have updated guidelines to encourage inclusion of pregnant people in some trials, but the practical challenges in trial design and recruitment mean the anticipated improvements may take years.

In summary, the evidence both supports the importance of expanding research in pregnancy and underscores persistent uncertainties that complicate clinical decision-making.

Why it matters

Understanding medication safety in pregnancy is critical for both maternal and child health. Medication decisions during pregnancy can have profound impacts, from preventing serious maternal health complications to avoiding preventable fetal harm.

The historical exclusion of pregnant individuals from trials and the resultant slow accumulation of safety data places pregnant people and their healthcare providers in a difficult position, often forcing decisions based on incomplete or inconclusive information. This can introduce anxiety, inconsistent clinical practices, and potentially preventable adverse outcomes.

Developing robust systems to generate and synthesize pregnancy medication safety data more efficiently and comprehensively can improve informed decision-making, reduce preventable harm, and guide safer prescribing practices globally.

What to verify next

  • Follow emerging clinical trials data on medication use in pregnancy, especially those undertaken under new regulatory guidelines promoting inclusion of pregnant people.
  • Monitor developments in international registry databases and whether legislative mandates for pharmaceutical-driven pregnancy exposure studies are implemented or effective.
  • Evaluate advances in pharmacokinetic, placental transfer, and biomarker research as complementary methods to epidemiological findings.
  • Assess how studies from low- and middle-income countries emerge and whether findings align or differ significantly from high-income settings.
  • Look for consensus guidelines or frameworks developed by regulatory, academic, and clinical stakeholders designed to standardize observational safety studies in pregnancy.

Readers are encouraged to consult the original source for detailed study references, methodological discussions, and the full scope of the editorial’s recommendations.

Source & verification

Primary source: PLOS Medicine · November 16, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…